Samsung Medical Center

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1994-01-01

Employees: 501

Market Cap: -

Website: http://www.samsunghospital.com

Clinical Trials

Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX

Phase 4

Completed

Conditions: Metastatic Non-Small Cell Lung Carcinoma

Interventions: Drug: Pembrolizumab Injection

First Posted Date: 2017-05-01

Last Posted Date: 2024-12-03

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 50

Registration Number: NCT03134456

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Young Breast Cancer Cohort Study

Conditions: Breast Cancer

First Posted Date: 2017-04-27

Last Posted Date: 2017-04-27

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 2000

Registration Number: NCT03131089

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold

Phase 4

Terminated

Conditions: Coronary Artery Disease
Atherosclerosis
Stents

Interventions: Drug: Clopidogrel
Drug: Ticagrelor
Drug: Aspirin

First Posted Date: 2017-04-18

Last Posted Date: 2024-04-22

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 25

Registration Number: NCT03119012

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Prospective Cohort for Adult Hemophagocytosis

Recruiting

Conditions: Hemophagocytic Lymphohistiocytoses

Interventions: Drug: Steroids
Drug: Etoposide

First Posted Date: 2017-04-17

Last Posted Date: 2024-08-07

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 81

Registration Number: NCT03117010

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

Recruiting

Conditions: Lymphoma, Non-Hodgkin
Lymphoma, Hodgkin

Interventions: Drug: Chemotherapy

First Posted Date: 2017-04-17

Last Posted Date: 2024-12-02

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 600

Registration Number: NCT03117036

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment

Not Applicable

Completed

Conditions: Insulin-dependent Diabetes Mellitus
Diabetes Mellitus
Insulin Hypoglycemia

Interventions: Device: Algorithm-based feedback messages
Device: Personal Health Record

First Posted Date: 2017-04-13

Last Posted Date: 2019-04-05

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 112

Registration Number: NCT03112343

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2

Withdrawn

Conditions: Biliary Tract Cancer

Interventions: Drug: Fluorouracil
Drug: Irinotecan Hydrochloride
Drug: leucovorin calcium

First Posted Date: 2017-04-12

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Registration Number: NCT03110510

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2

Conditions: Biliary Tract Cancer

Interventions: Drug: Pemetrexed 500 MG
Drug: Erlotinib

First Posted Date: 2017-04-12

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 44

Registration Number: NCT03110484

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Phase 2

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: MK3475

First Posted Date: 2017-04-12

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 33

Registration Number: NCT03110328

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification

Phase 2

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: vistusertib (AZD2014)

First Posted Date: 2017-04-10

Last Posted Date: 2018-09-20

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 4

Registration Number: NCT03106155

Locations: 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy